

Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study

Ha-Lim Jeon, Jun Soo Kwon, So-Hee Park and Ju-Young Shin

Background

Epidemiological data on the association between mental disorders and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) severity are limited.

Aims

To evaluate the association between mental disorders and the risk of SARS-CoV-2 infection and severe outcomes following COVID-19.

Method

We performed a cohort study using the Korean COVID-19 patient database based on national health insurance data. Each person with a mental or behavioural disorder (diagnosed during the 6 months prior to their first SARS-CoV-2 test) was matched by age, gender and Charlson Comorbidity Index with up to four people without mental disorders. SARS-CoV-2-positivity risk and the risk of death or severe events (intensive care unit admission, use of mechanical ventilation and acute respiratory distress syndrome) post-infection were calculated using conditional logistic regression analysis.

Results

Among 230 565 people tested for SARS-CoV-2, 33 653 (14.6%) had mental disorders; 928/33 653 (2.76%) tested SARS-CoV-2 positive and 56/928 (6.03%) died. In multivariable analysis using

the matched cohort, there was no association between mental disorders and SARS-CoV-2-positivity risk (odds ratio OR = 0.95; 95% CI 0.87–1.04); however, a higher risk was associated with schizophrenia-related disorders (OR = 1.50; 95% CI 1.14–1.99). Among confirmed COVID-19 patients, the mortality risk was significantly higher in patients with than in those without mental disorders (OR = 1.99, 95% CI 1.15–3.43).

Conclusions

Mental disorders are likely contributing factors to mortality following COVID-19. Although the infection risk was not higher for people with mental disorders overall, those with schizophrenia-related disorders were more vulnerable to infection.

Keywords

Mental disorders; mortality; COVID-19; SARS-CoV-2 infection; schizophrenia.

Copyright and usage

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing pandemic. In the absence of universally available approved vaccines and evidence-based pharmacological therapy for the disease,¹ it is crucial that governments and clinical practitioners identify vulnerable populations and establish specific prevention and treatment strategies. To date, older age, obesity, smoking, cardiovascular disease, diabetes, chronic obstructive pulmonary disease and hypertension have been identified as risk factors for COVID-19.^{2–4} However, there is little epidemiological evidence on the effect of mental disorders, despite raised concerns about increased risk of COVID-19 among people with mental illness.^{5,6}

People with mental disorders may be more vulnerable to viral or bacterial infection than those without these disorders, since various risk factors, such as unhealthy lifestyle and poor socioeconomic background, are often more prevalent in this population.^{7,8} These individuals' low cognitive ability and poor awareness of risk overall may also increase the infection risk.⁶ Moreover, once infected, mentally ill patients may also have a higher risk of severe adverse outcomes, because of their communication difficulties and physicians' discrimination against or negative attitude towards them. These problems may delay medical interventions for COVID-19, worsening prognosis.^{9,10} Furthermore, such individuals tend to be highly susceptible to stress, and excessive stress caused by restriction of social activities and fear of the epidemic may lead to suppressed immune responses.¹¹

Aims

Given that mental disorders are highly prevalent worldwide (pooled prevalence estimate: 17.6% across 59 countries),¹² investigating the relationship between mental disorders and SARS-CoV-2 infection and severity is important for public health. Here, we assessed the association between mental disorders and the risk of SARS-CoV-2 positivity. We also evaluated the risk of death and severe events (defined as intensive care unit (ICU) admission, use of mechanical ventilation and acute respiratory distress syndrome) among confirmed COVID-19 patients with mental disorders, using a nationwide cohort of people who underwent testing for SARS-CoV-2.

Method

Study design and data source

We conducted a population-based cohort study using the National Health Insurance claims data from the Health Insurance Review & Assessment service (HIRA) linked to the Korea Disease Control and Prevention Agency (KDCA) data. Data were collected up to 15 May 2020 and included demographic and clinical information and a 3-year medical history of people who underwent COVID-19 screening during the pandemic. Information on confirmed COVID-19 patients and those who died from COVID-19 was retrieved from the KDCA data to improve the internal validity of the database.

Clinical information included disease diagnosis, procedures, in-patient medication orders and prescriptions from all medical institutions in Korea. Disease information was recorded according to ICD-10. Information on the use of these anonymised data can be obtained from <https://hira-covid19.net/>.

Study population

We constructed two study cohorts: (a) a cohort of people with or without mental disorders who underwent testing for SARS-CoV-2 from 1 December 2019 to 15 May 2020, to investigate the risk of testing positive for SARS-CoV-2 and (b) a subcohort of confirmed COVID-19 patients from among the first cohort, to assess the risk of mortality and severe events following COVID-19. Laboratory confirmation of SARS-CoV-2 was based on diagnostic reverse transcription polymerase chain reaction (RT-PCR) tests, as recommended by the World Health Organization.

Assessment of mental disorders

We classified people who had a diagnostic code for mental and behavioural disorders (ICD-10 codes: F00–F99) at least once within 6 months prior to the first date of COVID-19 testing as individuals with mental disorders, and the rest as individuals without mental disorders. We selected a 6-month period to examine whether having psychiatric symptoms or mental disorder characteristics at the point of potential exposure to the virus affected the risk of infection or severity of outcomes. Individuals with mental disorders were matched with four controls without mental disorder diagnoses, according to age (± 2 years), gender and Charlson Comorbidity Index (CCI), which was assessed over 1 year before the first COVID-19 testing. This matching was conducted separately for the overall cohort and the subcohort.

Outcome ascertainment

Confirmed COVID-19 patients were ascertained from the KDCA database. To measure COVID-19 severity, we identified two endpoints: death (primary end-point) and severe events (secondary end-point). Death cases were also identified using the KDCA variable, which defined a death case as all-cause death in a patient with laboratory-confirmed SARS-CoV-2 infection. We designated three health outcomes after infection as severe events: ICU admission (National Procedure Codes (NPC): AH190, AH290, AH390, AH110, AH210, AJ001, AJ003, AJ004, AJ005, AJ006, AJ007, AJ008, AJ009, AJ100, AJ200, AJ101, AJ102, AJ201 and AJ202), use of mechanical ventilation (NPC: M0850, M0857, M0858, M0860, M5830, M5850, M5857, M5858, M5860, MM360 and MM400) and acute respiratory distress syndrome (ICD-10: J80 and P22).

Potential confounders

Participants' demographic information (type of insurance and residential area) and clinical baseline characteristics (comorbidities and use of medications) during 1 year prior to the first date of SARS-CoV-2 testing were considered as potential confounders, for which adjustments were made in a statistical model. We selected comorbidities that may be associated with mental disorders and that could be risk factors for infection or worse prognosis, as follows: diabetes (E10–E14), hypertension (I10–I15), heart failure (I11.0, I13.0, I13.2, I42 and I50), stroke (I60–I64), myocardial infarction (I21–I22 and I252), asthma (J45–J46), chronic obstructive pulmonary disease (J41–J44), renal disease (I12, I13.1, N03.2–N03.7, N05.2–N05.7, N18, N19, N25.0, Z49.0–Z49.2, Z94.0 and Z99.2), liver disease (B15–B19, K70, K71.3–K71.5, K71.7, K72.1, K72.9, K73, K74 and K76), cancer (registration codes: V193, V194 and V027)

and pneumonia (J12–J18). The use of medications that were likely to exert confounding effects was considered: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, thiazide diuretics, anticoagulants, anticonvulsants, digoxin, insulin, non-insulin glucose-lowering agents, non-steroidal anti-inflammatory drugs, acetaminophen and narcotic analgesics.

Statistical analysis

Continuous variables are described as mean and standard deviation (s.d.) and categorical variables are described by frequency and percentage. We calculated the standardised difference to compare the distribution of baseline characteristics between the group with and the group without mental disorders. Standardised differences greater than 0.1 were considered as imbalances of covariates.

We computed the percentages of individuals who were SARS-CoV-2 positive among individuals with and without mental disorders, using a cohort of individuals who underwent a SARS-CoV-2 test before and after matching. Odds ratios (ORs) for SARS-CoV-2 infection and their 95% confidence intervals (CIs) were calculated using a logistic regression model for the unmatched cohort and a conditional logistic regression model for the age-, gender- and CCI-matched cohorts, with adjustment for insurance type (health insurance or medical aid), residential area (metropolitan, urban or rural), comorbidities and the use of medications.

To examine the effect of mental disorders on COVID-19 severity, we calculated the percentages of individuals who died or experienced severe events among patients with a positive SARS-CoV-2 test. We analysed data obtained before and after matching, according to the presence or absence of a mental disorder. Likewise, logistic regression and conditional logistic regression analyses were used for the unmatched and matched cohorts respectively to estimate ORs for mortality and severe events. We adjusted ORs for the same variables used in the analysis of the risk of a positive SARS-CoV-2 test.

Subgroup analyses were conducted to estimate the risk of SARS-CoV-2 infection and severe COVID-19 in individuals with two pre-specified categories of ICD-10 mental disorder (schizophrenia, schizotypal and delusional disorders (F20–F29) and mood disorders (F30–F39)) as compared with individuals without mental disorders. These two conditions were selected as severe mental disorders; the lifestyles and symptoms of individuals with these diseases may have different effects on the risks. Additionally, we also classified and analysed individuals by recent use (within 30 days prior to their first SARS-CoV-2 test) of antipsychotics, since some antipsychotics exert immunomodulatory effects that could negatively affect COVID-19 prognosis.¹³ For subgroup analyses on the risk of severe outcomes among confirmed COVID-19 patients, we adjusted for only some variables as covariates in the model, to avoid problems of multicollinearity and overfitting, particularly when the number of potential confounders is large with respect to the study size.^{14,15} We selected variables that were regarded as clinically important, remained unbalanced between the two groups after matching and were more prevalent in patients with than in those without mental disorders (insurance type, diabetes, pneumonia, use of beta-blockers and anticonvulsants).

As a sensitivity analysis, we applied various definitions of individuals with mental disorders: (a) individuals with ≥ 2 diagnostic codes for mental and behavioural disorders within 6 months prior to their first COVID-19 test; (b) individuals who had a record of a diagnostic code and psychiatric medication within 6 months; (c) individuals with a diagnostic code within 30 days; and (d) individuals with a diagnostic code within 1 year. We also calculated the E-value to assess the robustness of the association between mental disorders and COVID-19 mortality to potential unmeasured

confounders. The E-value is the minimum strength of association that an unmeasured confounder would need to have with both the treatment and the outcome on the risk ratio scale to explain away the observed treatment–outcome association.¹⁶ If the calculated E-value is large, strong unmeasured confounders would be needed to explain away an effect estimate fully.

All analyses were conducted using the SAS Enterprise Guide version 6.1 for Windows provided by the HIRA (SAS Institute Inc., Cary, NC, USA). Two-sided *P*-values <0.05 were considered statistically significant.

Ethics approval

We assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants/patients were approved by the Institutional Review Board of the Sungkyunkwan University in Korea (IRB number: SKKU-2020-05-012). The need to obtain informed consent from participants was waived owing to the nature of this observational study.

Results

Characteristics of the study population

A total of 230 565 individuals had undergone a laboratory test for SARS-CoV-2 as of 15 May 2020. Among them, 33 653 (14.6%) had mental disorders and 196 912 (85.4%) did not (Fig. 1). The mean ages of those with and without mental disorders were 62.4 years (s.d. = 21.4) and 44.5 years (s.d. = 20.6) respectively (supplementary Table 1, available at <https://doi.org/10.1192/bjp.2020.251>). For 24 558 individuals with mental disorders, 97 966 controls were matched by age, gender and CCI. In the matched cohort, the mean age of the two groups was about 55 years, and 45.7% were male (Table 1). We identified 7077 people with confirmed COVID-19 in the first study cohort. Of these COVID-19 patients, 928 (13.1%) had mental disorders and 6149 (86.9%) had no mental disorders. After matching, there were 734 patients in the mental disorder group and 2817 in the reference group. The baseline covariates of the matched cohort were relatively well-balanced compared with those of the unmatched cohort.

The risk of SARS-CoV-2 positivity in individuals with mental disorders

In the unmatched cohort, 2.76% (928) individuals with mental disorders tested SARS-CoV-2 positive, compared with 3.12% (6149) without mental disorders (Table 2). The adjusted OR for a SARS-CoV-2-positive test in patients with mental disorders was 0.99 (95% CI 0.92–1.07) compared with those without mental disorders. After matching, the percentage of SARS-CoV-2-positive patients in both groups was approximately 3.0%, and the fully adjusted OR was 0.95 (95% CI 0.87–1.04).

The risk of severe COVID-19 in individuals with mental disorders

Among the 928 COVID-19 patients with mental disorders, 56 (6.03%) died and 44 (4.74%) experienced severe events (Table 2). The percentages of COVID-19 patients without mental disorders who died or had severe events were 0.89 and 2.11% respectively. The ORs of death and severe events were 3.93 (95% CI 2.57–6.03) and 1.47 (95% CI 0.99–2.19) respectively. In the matched cohort, 27 (3.68%) of the 734 COVID-19 patients with mental disorders

and 49 (1.74%) of the 2817 COVID-19 patients without mental disorders died. Compared with patients without mental disorders, the risk of death was increased in multivariable analysis (OR = 1.99; 95% CI 1.15–3.43). The percentage of patients who experienced severe events was 4.36% (32/734) in the mental disorders group and 3.48% (98/2817) in the reference group. The association between mental disorders and severe events was not statistically significant (OR = 1.15; 95% CI 0.73–1.82).

Subgroup analysis

When we repeated the analysis on the subgroup of individuals with schizophrenia, schizotypal or delusional disorders or mood disorders, the adjusted ORs for the risk of SARS-CoV-2 infection were 1.50 (95% CI 1.14–1.99) in those with schizophrenia, schizotypal or delusional disorders and 0.76 (95% CI 0.66–0.88) in those with mood disorders (Fig. 2). The risk of mortality and severe events after SARS-CoV-2 infection was higher in individuals with schizophrenia, schizotypal or delusional disorders than in those without mental disorders, but the effect was not statistically significant (death: adjusted OR = 2.25; 95% CI 0.36–14.03; severe events: adjusted OR = 1.27; 95% CI 0.37–4.37). Compared with those without mental disorders, COVID-19 patients with mood disorders had a higher risk of death (adjusted OR = 2.33; 95% CI 0.96–5.66) but not of severe events (adjusted OR = 0.71; 95% CI 0.32–1.58).

In the analysis based on the recent use of antipsychotics, no increased risk of SARS-CoV-2 infection was observed in either group: adjusted OR = 0.90 (95% CI 0.74–1.08) in individuals with mental disorders who used antipsychotics recently; adjusted OR = 0.97; 95% CI 0.88–1.08 in individuals with mental disorders who did not use antipsychotics. In terms of severe outcomes, the risks of death were higher, regardless of the use of antipsychotics, although these risks were not statistically significant: adjusted OR = 2.39 (95% CI 0.88–6.51) in COVID-19 patients who used antipsychotics; adjusted OR = 1.59 (95% CI 0.83–3.07) in those who did not. Additionally, patients with mental disorders who used antipsychotics were also likely to have a higher risk of severe events (adjusted OR = 1.69; 95% CI 0.70–4.05), whereas the risk was not higher among those who did not use antipsychotics (adjusted OR = 0.79; 95% CI 0.45–1.39).

Sensitivity analysis

The results of analyses using the four different definitions of individuals with mental disorders were mostly consistent with those from the main analysis (supplementary Fig. 1). No increased risk of SARS-CoV-2 infection was observed, but the risks of death and severe events were consistently higher in patients with than in those without mental disorders, regardless of the definition used. The E-value obtained from the estimate of mortality risk was 3.39.

Patient and public involvement

Patients and the public could not be involved in the design, conduct, reporting or dissemination plans of our research, since we used de-identified patient data.

Discussion

Evidence from this nationwide cohort study suggested that mental disorders are not associated with the risk of SARS-CoV-2 infection but are likely to be associated with a higher mortality risk on infection. As regards severe events, we found no evidence of increased risk among confirmed COVID-19 patients with, compared with those without, mental disorders. The risk of a SARS-CoV-2-positive




Fig. 1 Flowchart of study population selection from Korea's nationwide coronavirus disease 2019 (COVID-19) database from 1 December 2019 to 15 May 2020.

Matching, each individual with a mental or behavioural disorder was matched by age, gender and Charlson Comorbidity Index with up to four individuals without mental disorders; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

test was higher in individuals with schizophrenia, schizotypal or delusional disorders than in those without mental disorders. The COVID-19-related mortality risk was higher regardless of the two pre-specified types of mental disorder (schizophrenia, schizotypal and delusional disorders; mood disorders) and recent use of antipsychotics, although not statistically significant.

Our data showed an increased relative mortality risk among individuals with mental disorders who have had COVID-19. This finding is in line with a study that found a significant relationship between mental disorders and cause-specific mortality, including death related to infectious diseases.¹⁷ The positive association between mental disorders and excess mortality from medical conditions is known to stem from multiple factors. Since mental illness is generally associated with an unhealthy lifestyle (e.g. smoking and alcohol consumption) and a low socioeconomic status,^{18–20} these factors may also have contributed to a worse prognosis of COVID-19. Furthermore, health inequality in people with mental illness has been suggested as an important contributor to poor physical health outcomes.^{21,22} Stigma and discrimination towards mental illness and poor communication skills of people with mental disorders may hamper proper and timely provision of medical intervention for COVID-19 and therefore cause more severe health outcomes.

Additionally, the use of antipsychotics may increase the risk of death or severe events. Some antipsychotic medications have immunomodulatory effects:¹³ chlorpromazine and clozapine can affect the production of cytokines, resulting in suppression of the immune response. However, in the subgroup analysis, we found a higher risk of death in COVID-19 patients with than in those without mental disorders, irrespective of the use of antipsychotics. Although the effects of antipsychotics cannot be completely excluded, our findings suggest that having a mental disorder alone may increase the risk of mortality following COVID-19.

Previous studies found a positive association between severe mental illness and microbial or viral infection (pneumonia, human immunodeficiency virus, hepatitis B and hepatitis C).^{7,8} In our study, individuals with schizophrenia-related disorders were

at higher risk of SARS-CoV-2 infection, although no association was observed among individuals with mental disorders overall. People with schizophrenia-related disorders may be more vulnerable to SARS-CoV-2 infection than those with other mental disorders because they are more likely to live in shared accommodation such as psychiatric hospitals. Unlike patients in general hospitals, those in psychiatric hospitals commonly participate in group activities, creating conditions favourable for virus transmission. Additionally, teaching such patients to follow personal control measures would be difficult, given their impaired cognitive ability. In contrast, we found a decreased risk of infection in people with mood disorders compared with those without mental disorders. One possible explanation may be that people with mood disorders tend to engage in fewer social activities than would healthy individuals, reducing the chance of exposure to the virus. Indeed, COVID-19 has spread among young and healthy people owing to the highly contagious nature of the virus, although the fatality rate is low.^{23,24}

Strengths and limitations

Our study had several strengths. We used a nationwide COVID-19 database that includes medical histories of all COVID-19 patients in Korea, which strengthens the generalisability of our results. Moreover, we enhanced the internal validity of our findings by using information on patients with confirmed COVID-19 and those who died from COVID-19 obtained from the KDCA. The Korean government has strictly managed people with confirmed and suspected COVID-19. According to the government's response system, all inbound travellers are monitored and tested if they present with fever or respiratory symptoms. If a person tests positive for SARS-CoV-2, all primary contacts of that person are identified by epidemiological investigation and receive a test if they exhibit symptoms during a 14-day self-quarantine period. COVID-19 patients must be admitted to infectious disease hospitals or accommodated in residential treatment centres, depending on their

Table 1 Baseline characteristics of individuals with and without mental disorders who underwent tests for SARS-CoV-2 and those who were diagnosed with COVID-19 after age, gender and Charlson Comorbidity Index matching

Characteristics	Individuals who underwent tests for SARS-CoV-2 (n = 122 524)			Individuals who were diagnosed with COVID-19 (n = 3551)		
	With mental disorder (n = 24 558)	Without mental disorder (n = 97 966)	aSD	With mental disorder (n = 734)	Without mental disorder (n = 2817)	aSD
Age, years: mean (s.d.)	54.9 (20.2)	54.7 (20.0)	0.01	56.3 (16.6)	55.4 (16.2)	0.06
Male, n (%)	11 232 (45.7)	44 818 (45.7)	0.00	308 (42.0)	1174 (41.7)	0.01
Residential district, n (%)			0.08			0.20
Metropolitan	6748 (27.5)	29 659 (30.3)		38 (5.2)	247 (8.8)	
Urban	5350 (21.8)	22 066 (22.5)		49 (6.7)	286 (10.2)	
Rural	12 460 (50.7)	46 241 (47.2)		647 (88.1)	2284 (81.1)	
Hospital admission for COVID-19, n (%) ^a	–	–		719 (98)	2777 (98.6)	0.05
Charlson Comorbidity Index, mean (s.d.)	1.2 (1.5)	1.2 (1.8)	0.05	0.73 (1.1)	0.68 (1.1)	0.04
0	11 061 (45)	44 222 (45.1)		440 (59.9)	1742 (61.8)	
1	5451 (22.2)	21 749 (22.2)		123 (16.8)	473 (16.8)	
2	4120 (16.8)	16 393 (16.7)		119 (16.2)	428 (15.2)	
3+	3926 (16)	15 602 (15.9)		52 (7.1)	174 (6.2)	
Comorbidities, n (%) ^b						
Diabetes mellitus	4788 (19.5)	17 857 (18.2)	0.03	139 (18.9)	398 (14.1)	0.13
Hypertension	7532 (30.7)	28 216 (28.8)	0.04	210 (28.6)	704 (25)	0.08
Heart failure	865 (3.5)	4526 (4.6)	0.06	14 (1.9)	69 (2.4)	0.04
Stroke	1666 (6.8)	4916 (5)	0.08	36 (4.9)	99 (3.5)	0.07
Myocardial infarction	299 (1.2)	1259 (1.3)	0.01	1 (0.1)	24 (0.9)	0.10
Asthma	2698 (11)	9015 (9.2)	0.06	44 (6)	154 (5.5)	0.02
COPD	5684 (23.1)	20 973 (21.4)	0.04	112 (15.3)	381 (13.5)	0.05
Renal disease	1193 (4.9)	5105 (5.2)	0.02	4 (0.5)	25 (0.9)	0.04
Liver disease	3334 (13.6)	13 447 (13.7)	0.00	78 (10.6)	320 (11.4)	0.02
Cancer	2619 (10.7)	8143 (8.3)	0.08	36 (4.9)	105 (3.7)	0.06
Pneumonia	2186 (8.9)	14 415 (14.7)	0.18	21 (2.9)	150 (5.3)	0.13
Taking medications, n (%) ^b						
ACE inhibitors	333 (1.4)	1481 (1.5)	0.01	10 (1.4)	33 (1.2)	0.02
Angiotensin II receptor blockers	6204 (25.3)	23 798 (24.3)	0.02	160 (21.8)	568 (20.2)	0.04
β-blockers	7909 (32.2)	14 273 (14.6)	0.43	201 (27.4)	275 (9.8)	0.47
Calcium channel blockers	6281 (25.6)	23 184 (23.7)	0.04	152 (20.7)	473 (16.8)	0.10
Thiazide diuretics	2354 (9.6)	7918 (8.1)	0.05	60 (8.2)	211 (7.5)	0.03
Anticoagulants	9278 (37.8)	30 982 (31.6)	0.13	183 (24.9)	571 (20.3)	0.11
Anticonvulsants	6782 (27.6)	12 647 (12.9)	0.37	162 (22.1)	196 (7)	0.44
Digoxin	263 (1.1)	1342 (1.4)	0.03	4 (0.5)	10 (0.4)	0.03
Insulin	1962 (8)	7695 (7.9)	0.01	36 (4.9)	59 (2.1)	0.15
Non-insulin glucose lowering agents	3950 (16.1)	15 950 (16.3)	0.01	127 (17.3)	363 (12.9)	0.12
NSAIDs	21 351 (86.9)	81 161 (82.8)	0.12	580 (79)	2278 (80.9)	0.05
Acetaminophen	18 896 (76.9)	67 658 (69.1)	0.18	510 (69.5)	1797 (63.8)	0.12
Narcotic analgesics	15 397 (62.7)	54 820 (56)	0.14	426 (58)	1506 (53.5)	0.09
Treatment for COVID-19 ^a						
Hydroxychloroquine	–	–		260 (35.4)	1013 (36)	0.01
Lopinavir/ritonavir	–	–		345 (47)	1287 (45.7)	0.03
Azithromycin	–	–		0 (0)	0 (0)	0.00
Glucocorticoid	–	–		52 (7.1)	180 (6.4)	0.03
Interferon beta	–	–		6 (0.8)	9 (0.3)	0.07

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; aSD, absolute standardised difference; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs.
a. Hospital admission and treatment for COVID-19 were assessed from the cohort entry date to the end of the study period.
b. Comorbidities and the use of medications were assessed for the year before the cohort entry date.

disease severity, and receive regular check-ups until they meet the criteria for discharge. Therefore, underestimation of the number of patients with confirmed COVID-19 and the number who died would be trivial in this study. Furthermore, owing to the strict patient management system in Korea, confounding effects by differences in access to medical facilities or support between patients with and without mental disorders would be minor. People with mental disorders may have different medical behaviours than those without such disorders, which may cause a difference in medical access; however, the difference would not exist in the study cohort since all confirmed COVID-19 patients were placed in quarantine facilities and managed by the government.

This study also had some limitations. First, covariates regarding lifestyle (smoking status and alcohol consumption) and

socioeconomic status (education and income level) of participants were not included in the analytic model. The National Health Insurance database was constructed on the basis of claims data; therefore, these variables were not available. Although unmeasured confounders are associated with worse outcomes after SARS-CoV-2 infection, the results of the sensitivity analysis suggest that the observed OR of 1.99 could be explained away only by an unmeasured confounder associated with both mental disorder and death that had a 3.39-fold risk ratio. Hence, our findings are robust unless an unmeasured confounder of such magnitude exists. Second, we identified severe events on the basis of diagnostic and procedural codes, which were recorded for administrative purposes; thus, there was potential for misclassification of outcomes. However, a validation study comparing the claims database and

Table 2 Risk of a positive test for SARS-CoV-2 and severe outcomes following COVID-19 in individuals with mental disorders compared with those without mental disorders

	Individuals, <i>n</i>	Events, <i>n</i>	Events, ^a %	Odds ratio	
				Crude (95% CI)	Adjusted ^b (95% CI)
SARS-CoV-2-positive patients among individuals who received a SARS-CoV-2 test					
Before matching					
With mental disorder	33 653	928	2.76	0.88 (0.82–0.94)	0.99 (0.92–1.07)
Without mental disorder	196 921	6149	3.12	1.00 (ref.)	1.00 (ref.)
After matching ^c					
With mental disorder	24 558	756	3.08	1.02 (0.94–1.11)	0.95 (0.87–1.04)
Without mental disorder	97 966	2965	3.03	1.00 (ref.)	1.00 (ref.)
Patients who experienced severe outcomes following COVID-19					
Before matching					
Death (primary)					
With mental disorder	928	56	6.03	7.12 (4.87–10.39)	3.93 (2.57–6.03)
Without mental disorder	6149	55	0.89	1.00 (ref.)	1.00 (ref.)
Severe events ^d (secondary)					
With mental disorder	928	44	4.74	2.31 (1.63–3.27)	1.47 (0.99–2.19)
Without mental disorder	6149	130	2.11	1.00 (ref.)	1.00 (ref.)
After matching ^c					
Death (primary)					
With mental disorder	734	27	3.68	1.94 (1.17–3.21)	1.99 (1.15–3.43)
Without mental disorder	2817	49	1.74	1.00 (ref.)	1.00 (ref.)
Severe events ^d (secondary)					
With mental disorder	734	32	4.36	1.27 (0.84–1.93)	1.15 (0.73–1.82)
Without mental disorder	2817	98	3.48	1.00 (ref.)	1.00 (ref.)

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; ref. reference.
 a. Number of events/number of individuals ×100.
 b. Adjusted for type of insurance, residential area, comorbidities and the use of medications.
 c. The cohort matched by age, gender and Charlson Comorbidity Index.
 d. Defined as intensive care unit (ICU) admission, use of mechanical ventilation and acute respiratory distress syndrome.




Fig. 2 Forest plot summarising the results of subgroup analyses by two categories of mental disorder and the recent use of antipsychotics after age, gender and Charlson Comorbidity Index matching.

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019.
 a. The risks of a positive test for SARS-CoV-2 were adjusted for the type of insurance, residential area, comorbidities and the use of medications. The risks of death and severe events were adjusted for the type of insurance, a medical history of diabetes and pneumonia, and use of beta-blockers and anticonvulsants.
 b. Schizophrenia, schizotypal and delusional disorders.
 c. Antipsychotic use within 30 days prior to a first SARS-CoV-2 test.
 d. Defined as intensive care unit (ICU) admission, use of mechanical ventilation and acute respiratory distress syndrome.

in-patients' hospital medical records reported that the overall agreement of diagnosis was 82.0%.²⁵ Procedural codes that are directly related to payment from National Health Insurance are also likely to be highly valid. Third, the risk of SARS-CoV-2 infection might be biased owing to the different probabilities of receiving the test between populations with and without mental disorders. If people with mental disorders were tested more in the absence of any symptoms of COVID-19, for preventive purposes, the risk of SARS-CoV-2 infection may be underestimated. However, it is unlikely that these people would have been included in our study because only people who had an epidemiological link or showed clinical symptoms of COVID-19 could receive a free test for SARS-CoV-2, covered by National Health Insurance in Korea. The percentage of people with mental disorders among people who received a test for SARS-CoV-2 was higher (14.6%) than among the general population in 2019 (6.5%, calculated using national statistics on the number of people who have records of mental and behavioural disorders from the Healthcare Bigdata Hub website of the HIRA). However, this may be due to several outbreaks of cluster infection at nursing homes or psychiatric hospitals, rather than these people being tested more commonly for preventive purposes. Last, although we utilised a database covering overall COVID-19 patients in Korea, the number of patients with mental disorders was not sufficient to evaluate the risk of death and severe events by subgroup analysis based on more subdivided disorder types, such as depression, anxiety and dementia. Further studies are needed to determine whether people with particular mental disorders have a higher risk of SARS-CoV-2 infection and severe COVID-19.

Implications

Although we found no association between overall mental disorders and the risk of SARS-CoV-2 infection among individuals who were tested, the risk was significantly higher in people with schizophrenia-related disorders than in those without mental disorders. Our results also suggest that mental disorders are likely associated with an increased risk of death following COVID-19. Psychiatrists should therefore inform patients and their caregivers about the risk of SARS-CoV-2 infection and guide them to comply with preventive measures. Furthermore, clinicians and healthcare policy makers need to pay more attention to patients with mental disorders during the COVID-19 pandemic and establish preventive strategies for them.

Ha-Lim Jeon , School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; **Jun Soo Kwon** , Department of Psychiatry, Seoul National University College of Medicine, Republic of Korea; and Department of Neuropsychiatry, Seoul National University Hospital, Republic of Korea; and Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Republic of Korea; and Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Republic of Korea; **So-Hee Park** , School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; **Ju-Young Shin** , School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; and Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea

Correspondence: Associate Professor Ju-Young Shin. Email: shin.jy@skku.edu

First received 5 Aug 2020, final revision xxxx, accepted 30 Nov 2020

Supplementary material

Supplementary material is available online at <https://doi.org/10.1192/bjp.2020.251>

Data availability

The data that support the findings of this study are available from the Health Insurance Review & Assessment service (HIRA) in South Korea. Restrictions apply to the availability of these data, which were used under licence for this study.

Acknowledgements

We thank the healthcare professionals dedicated to treating COVID-19 patients in Korea, the Ministry of Health and Welfare, and the HIRA of South Korea for sharing invaluable national health insurance claims data in a prompt manner. We especially thank Do-Yeon Cho and Yujin Lee of the HIRA for executing the analysis software. We also thank Ju Hwan Kim of Sungkyunkwan University and Editage (www.editage.co.kr) for English language editing.

Author contributions

H.-L.J. and J.-Y.S. designed the study. S.-H.P. analysed the data. H.-L.J., S.-H.P. and J.S.K. interpreted the data. H.-L.J. wrote the first draft. J.S.K. and J.-Y.S. critically revised the draft. All authors read and approved the final manuscript. As guarantor and corresponding author, J.-Y.S. had full access to the data, takes responsibility for the integrity of the data and controls the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI19C1233).

Declaration of interest

J.-Y.S. has received research grants from the Ministry of Food and Drug Safety, Ministry of Health and Welfare, the National Research Foundation of the Republic of Korea, and pharmaceutical companies, including Amgen, Pfizer, Hoffmann-La Roche, Dong-A ST and Yungjin.

References

- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. *JAMA* 2020; **324**: 782–93.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
- Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ* 2020; **368**: m1198.
- Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med* 2020; **180**: 1345–55.
- Druss BG. Addressing the COVID-19 pandemic in populations with serious mental illness. *JAMA Psychiatry* 2020; **77**: 891–2.
- Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. *Lancet Psychiatry* 2020; **7**: e21.
- Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. *Thorax* 2013; **68**: 171–6.
- Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. *Lancet Psychiatry* 2016; **3**: 40–8.
- Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børglum AD, Christensen MK, et al. Association between mental disorders and subsequent medical conditions. *N Engl J Med* 2020; **382**: 1721–31.
- Bailey EA, Wirtalla C, Sharoky CE, Kelz RR. Disparities in operative outcomes in patients with comorbid mental illness. *Surgery* 2018; **163**: 667–71.
- Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. *Psychol Bull* 2004; **130**: 601–30.
- Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. *Int J Epidemiol* 2014; **43**: 476–93.
- Pollmächer T, Haack M, Schulz A, Kraus T, Hinze-Selch D. Effects of anti-psychotic drugs on cytokine networks. *J Psychiatr Res* 2000; **34**: 369–82.
- Chen Q, Nian H, Zhu Y, Talbot HK, Griffin MR, Harrell FE Jr. Too many covariates and too few cases? A comparative study. *Stat Med* 2016; **35**: 4546–58.
- Greenland S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. *Int J Epidemiol* 2016; **45**: 565–75.
- VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med* 2017; **167**: 268–74.

- 17 Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. *Lancet* 2019; **394**: 1827–35.
- 18 Bellos S, Skapinakis P, Rai D, Zitko P, Araya R, Lewis G, et al. Cross-cultural patterns of the association between varying levels of alcohol consumption and the common mental disorders of depression and anxiety: secondary analysis of the WHO Collaborative Study on Psychological Problems in General Health Care. *Drug Alcohol Depend* 2013; **133**: 825–31.
- 19 Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. *JAMA* 2014; **311**: 172–82.
- 20 McLaughlin KA, Costello EJ, Leblanc W, Sampson NA, Kessler RC. Socioeconomic status and adolescent mental disorders. *Am J Public Health* 2012; **102**: 1742–50.
- 21 Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. *J Psychopharmacol* 2010; **24**(suppl 4): 61–8.
- 22 Wang JJ, Hsieh PF, Wang CJ. Long-term care nurses' communication difficulties with people living with dementia in Taiwan. *Asian Nurs Res* 2013; **7**: 99–103.
- 23 Ashour HM, Elkhatab WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. *Pathogens* 2020; **9**(3): 186.
- 24 Stone W. *Younger Adults are Increasingly Testing Positive for the Coronavirus*. KCRW Weekend Edition Sunday, 2020 (<https://www.kcrw.com/news/shows/weekend-edition-sunday/npr-story/880912184>).
- 25 Park EC, Jang SI, Jeon SY, Lee SA, Lee JE, Choi DW. *Assessment of Level of Agreement in Disease Codes between Health Insurance Claims Data and Medical Records*. Health Insurance Review & Assessment service, 2018 (<http://www.alio.go.kr/informationResearchView.do?seq=2343982>).



psychiatry in literature

The Sorrows of Young Werther: that which must not be read

Dori Zosmer 

In 1774, and over roughly 6 weeks of intensive writing, the 24-year-old Johann Wolfgang von Goethe published his semi-autobiographical book *The Sorrows of Young Werther*. It was an immediate success, arguably one of the first 'bestsellers', was hailed by Napoleon Bonaparte and even led to merchandise such as Werther-themed perfume.

The book was an important part of the German proto-Romantic literary movement known as Sturm und Drang, often translated as Storm and Stress. It is presented as a collection of letters written by Werther, a young artist, to his friend Wilhelm. Werther falls hopelessly in love with Charlotte, but she is already engaged to Albert and does not requite his love. Although the three become friends, Werther remains infatuated and becomes imprisoned in the ensuing love triangle. Eventually and after seeing no alternative, he borrows Albert's pistols and at midnight on Christmas Eve, shoots himself in the head. He dies an agonising 12 hours later.

While for Goethe the writing of this novel was cathartic, for his readers it led to alarming consequences. It is reputed that after reading the book, young men started taking their lives in a similar manner to Werther, wearing similar clothing and using similar pistols. A copy of the book was often found on their person. There is controversy about the details and numbers, but there was enough fear of contagion that the book was banned in countries such as Denmark and Italy. In the 1970s, researcher David Phillips coined the term 'Werther effect' to describe the phenomenon of copycat suicides, whereby publicised suicides are followed by spikes in suicides in the general population.

Goethe's still accessible book opens a plethora of ethical, psychoanalytic and philosophical discussion. The later-coined Werther effect gives pause for thought on how best to approach suicide prevention campaigns, and the ethical guidelines of media coverage. Indeed, through increasing knowledge we try to negotiate the see-saw, on one side inadvertently increasing suicide rates and on the other, like J.K. Rowling's infamous villain Voldemort, having a fear of mentioning it.

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

The British Journal of Psychiatry (2021)
218, 351. doi: 10.1192/bjp.2021.24